15 June 2020 : Clinical Research
LncRNA LINC00152 Increases the Aggressiveness of Human Retinoblastoma and Enhances Carboplatin and Adriamycin Resistance by Regulating MiR-613/Yes-Associated Protein 1 (YAP1) Axis
Ying Wang1CDE*, Danli Xin1ABCE, Lei Zhou1BCDFDOI: 10.12659/MSM.920886
Med Sci Monit 2020; 26:e920886
Table 1 Association of LINC00152 expression with clinicopathologic characteristics of retinoblastoma patients.
| Parameter | Case | LINC00152 expression | P value* | |
|---|---|---|---|---|
| High (n=18) | Low (n=18) | |||
| Sex | ||||
| Female | 16 | 7 | 9 | 0.714 |
| Male | 20 | 11 | 9 | |
| Age (years) | ||||
| ≤2 | 19 | 9 | 10 | 0.682 |
| >2 | 27 | 9 | 8 | |
| Tumor size (mm) | ||||
| ≤15 | 17 | 6 | 11 | 0.016 |
| >15 | 19 | 12 | 7 | |
| Degree of differentiation | ||||
| Well and moderately | 13 | 7 | 6 | 0.760 |
| Poorly | 23 | 11 | 12 | |
| ICRB staging system | ||||
| Group A–C | 14 | 4 | 10 | 0.008 |
| Group D–E | 22 | 14 | 8 | |
| Choroidal invasion | ||||
| No | 18 | 6 | 12 | <0.001 |
| Yes | 18 | 12 | 6 | |
| Optic nerve invasion | ||||
| No | 16 | 6 | 10 | 0.003 |
| Yes | 20 | 12 | 8 | |
| * Chi-square test. ICRB – International Classification of Retinoblastoma. | ||||